Join the conversation
Log in or create an account to leave a comment
Log In
[breathing heavily] PROFESSOR: This makes the user
increase their dose again at a fast rate. ‐ And is that dangerous? ‐ Absolutely. It's one of the reasons
why overdose rates are so much higher
on OxyContin. MICHAEL: These are
the new numbers, and you'll see
a significant difference from the initial
rollout figures
increase their dose again at a fast rate. ‐ And is that dangerous? ‐ Absolutely. It's one of the reasons
why overdose rates are so much higher
on OxyContin. MICHAEL: These are
the new numbers, and you'll see
a significant difference from the initial
rollout figures
Full Transcript
00:00:01.000 --> 00:00:04.212
[breathing heavily]
00:00:04.212 --> 00:00:06.297
PROFESSOR: This makes the user
increase their dose again
00:00:06.297 --> 00:00:07.673
at a fast rate.
00:00:07.673 --> 00:00:10.051
‐ And is that dangerous?
00:00:10.051 --> 00:00:11.026
‐ Absolutely.
00:00:11.026 --> 00:00:12.762
It's one of the reasons
why overdose rates
00:00:12.762 --> 00:00:14.806
are so much higher
on OxyContin.
00:00:14.806 --> 00:00:16.766
MICHAEL: These are
the new numbers,
00:00:16.766 --> 00:00:19.999
and you'll see
a significant difference
00:00:19.999 --> 00:00:21.187
from the initial
rollout figures.
Want This Clip in HD?
Upgrade for HD/4K downloads and unlimited access. Upgrade now →
Movie Summary
The series takes viewers to the epicenter of America's struggle with opioid addiction, from the boardrooms of Purdue Pharma, to a distressed Virginia mining community, to the hallways of the DEA.